Secarna Pharmaceuticals GmbH & Co. KG, an independent European antisense drug discovery and development company, and Orbit Discovery Ltd., a leader in the discovery of therapeutic peptide hits, announced a collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics.
True innovation in healthcare requires us to look beyond the obvious. For years, DNA sequencing has been the key pillar of precision medicine, offering insights into disease predispositions, mechanisms, and diagnosis that inform treatment.
